Coherus BioSciences Inc (Coherus) is a biopharmaceutical company that conducts research, development and commercialization of immunotherapies to treat cancer. The company markets Udenyca (pegfilgrastim-cbqv), a biosimilar of Neulasta, and Cimerli (ranibizumab-eqrn), a biosimilar of Lucentis, in the US. Coherus products find its application for the treatment of various therapeutic areas which includes nasopharyngeal carcinoma, hepatocellular carcinoma, non-small lung cancer, small cell lung cancer and solid tumors. It is evaluating Toripalimab’s pivotal clinical trial for the treatment of nasopharyngeal carcinoma. The company also plans to launch Humira, a biosimilar Yusimry (adalimumab-aqvh) in the current fiscal year. It collaborates with other organizations to develop drug candidates. Coherus is headquartered in Redwood City, California, the US.
Headquarters
United States of America
Address
C/O Dennis M. Lanfear, 201 Redwood Shores Parkway, Suite 200, Redwood City, California, 94065
Website
www.coherus.com
Telephone
1 650 6493530
No of Employees
294
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
CHRS (NASD)
Revenue (2022)
$211.0M
-35.4%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
-1.6%
(2022 vs 2021)
Market Cap*
$256.1M
Net Profit Margin (2022)
XYZ
-57.2%
(2022 vs 2021)
* As of and is in US$
Coherus BioSciences Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Pipeline | UDENYCA |
| Toripalimab: | YUSIMRY |
| Nasopharyngeal Carcinoma | CIMERLI |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Acquisitions/Mergers/Takeovers | In September, the company announced the acquisition of Surface Oncology, Inc, a clinical-stage immuno-oncology (I-O) company. |
| 2023 | Contracts/Agreements | In July, the company and Superior Biologics Inc entered into a national distribution agreement for YUSIMRY. |
| 2023 | Plans/Strategy | In June, the company announced its plans to launch YUSIMRY (adalimumab-aqvh). |
Competitor Comparison
| Key Parameters | Coherus BioSciences Inc | Pfizer Inc | F. Hoffmann-La Roche Ltd | Merck & Co Inc | AbbVie Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | Switzerland | United States of America | United States of America |
| City | Redwood City | New York | Basel | Kenilworth | North Chicago |
| State/Province | California | New York | - | New Jersey | Illinois |
| No. of Employees | 294 | 83,000 | 103,613 | 69,000 | 50,000 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Dennis M. Lanfear | Chief Executive Officer; President; Chairman | Executive Board | 2010 | 66 |
| McDavid Stilwell | Chief Financial Officer | Senior Management | 2021 | 51 |
| Rosh Dias, MD. | Chief Medical Officer | Senior Management | 2022 | - |
| Vladimir Vexler, Ph.D. | Chief Scientific Officer | Senior Management | 2018 | 64 |
| Sanjay Khare | Executive Vice President; Head - Immuno-oncology Research | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2023 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2023 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2023 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward